New Developments in Analgesia By Dr Susan Boyce, Dr Zahid Ali and Dr Raymond G. Hill Novel therapies for pain and headache are major medical needs and constitute a continued opportunity. Novel treatments are likely to arise from a better understanding of both the pathophysiology of clinical pain conditions and… Read More
Surrogate Endpoints In Cancer Trials By Professor Karol Sikora Over the next 20 years systematic programmes of cancer risk assessment will be established and cancer-preventive drugs will be developed. The ability to prevent cancer will dramatically increase the number of people who will need to regularly attend clinics. This article… Read More
Protein Arrays - New technology for the proteomics era By Dr Jeffrey P. Kiplinger The study of the human proteome will drive drug discovery in coming years; although how, when, and in what direction are a little uncertain at present. To build understanding of the role of the human protein… Read More
Stem Cells - The long march forward to the clinic By Dr Alan Colman The area of cellular therapeutics has never been readily embraced by 'Big Pharma', with ethical and regulatory issues even more complex and troublesome than proteins. Can stem cell therapy provide the key to unlocking a rich… Read More
By Professor Klaus Lindpaintner Pharmacogenetics represents a logical and consequent step in the history of medicine, but what are the immediate benefits and where do the hurdles lie in its implementation? It is common knowledge that today’s pharmacopea – in as much as it represents enormous progress if compared with… Read More
By Dr Doros Platika As the population ages, the scientific and medical communities are working to solve the challenges this changing demographic will place on society. Companies involved in the promising field of regenerative medicine are now on the cutting edge as it strives to promote longevity without disability. Regenerative… Read More
Protein Therapeutics - New ladders up the fruit tree By Dr Richard AG Smith Therapeutic proteins are often regarded as too technologically demanding, too costly, too restricted in routes or duration of administration or - in an era of massive opportunity provided by high throughput screening, combinatorial chemistry and genomics… Read More
Biologically Relevant Chemistry By Dr Stephen A. Hill A large proportion of R&D expenditure relates to the investigation of compounds which ultimately fail to reach the market as useful medicines. We discuss why early drug discovery - using high throughput, automated in vitro and in silico methods, must become the… Read More
e-R&D - The internet at work By Dr Alpheus Bingham and Dr Neil Bodick It is difficult to understand how the continuing growth of large monolithic Research & Development organisations can sustain the industry. With the economies of scale providing diminishing returns we examine the promise of e-R&D and explore… Read More
Modelling and simulation in drug development, promise and reality By Dr Mark Sale Modelling and simulation in drug development is not new. What is new is the vision for moving from a descriptive role (what happened) to a predictive and therefore decision making role. While seemingly attractive, important hurdles, both… Read More
The Genie in the Test Tube - From Gene to Gene Therapy: Part 2 By Dr Jan Steiner In the previous edition, we discussed gene therapy in terms of potential vectors and their applications. Now, we discuss the potential clinical uses of these constructs. To date, the main applications of… Read More
The promise of pharmacogenetics and pharmacogenomics By Dr Tim Peakman and Dr Steve Arlington Within the next 10 years the benefits of pharmacogenetics and pharmacogenomics will inevitably outweigh the disadvantages. But what are the commercial and legal implications for the pharmaceutical industry especially for companies who have lead candidates ready… Read More
High-throughput Crystallisation By Dr Sara Moran and Dr Lance Stewart With structure-based drug design on the increase can the development of high-throughput crystallisation fulfil its promise to revolutionise the drug discovery process? In an era when the development of drugs is hindered by the exorbitant costs of discovery and clinical… Read More
By Dr David C. U’Prichard It is almost axiomatic that the pharmaceutical R&D industry has not achieved in the last decade an increase in productivity (measured as high value NCEs) commensurate with the explosion of new biological information, chemistry techniques and information storage/retrieval/examination systems, let alone the real increase in… Read More
By Peter Ertl, Wolfgang Miltz, Bernhard Rohde and Paul Selzer Readily accessible tools with easy to use interfaces, especially integrated into regularly used desktop applications, can improve the impact of cheminformatics in pharmacological research. Starting either from a single molecule or from a larger data set, these tools provide information… Read More
By Michael P. Murphy, MSc Pharmacogenomics offers the opportunity to adopt a new paradigm in drug development. The pharmaceutical industry is faced with a number of challenges including relatively low productivity and success in bringing new drugs to market. Investors demand that pharmaceutical companies deliver several new drugs to the… Read More